Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesEndocrinologyblue cross blue shield - louisiana thyroid coverag…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedblue cross blue shield - louisianaPolicy AHS - G2045 - Thyroid Disease Testing

    Thyroid Disease Testing

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy AHS - G2045 - Thyroid Disease Testing alerts

    Get alerted when Policy AHS - G2045 - Thyroid Disease Testing changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Criteria for coverage of laboratory testing for thyroid function, antibodies, and related serum markers; governs when Blue Cross and Blue Shield of Louisiana will cover specific thyroid tests for members and how frequently they may be performed.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyThyroid Disease Testing
    Policy CodePolicy AHS - G2045 - Thyroid Disease Testing
    Change TypeSubstantive revision with new CC groups and clarified exclusions
    Effective DateSep 15, 2026
    Last ReviewSep 1, 2023
    Next Review DateN/A
    Key ActionStart evaluation with TSH and cascade to fT4/fT3 only when indicated; document clinical indication and applicable monitoring frequency.
    SourceLink
    POLICY UPDATE CHANGES

    CC1 was edited and divided into multiple criteria to create a cascade approach for TSH vs fT4/fT3/TT3, with new CC2, CC3, CC4 addressing follow-up and monitoring strategies.

    New CC2 (follow up testing for abnormal TSH results), new CC3 (monitoring of TSH and fT4 when conditions allow for initial monitoring of fT4 without requiring abnormal TSH), and new CC4 (monitoring of fT4 without additional measurement of TSH for secondary hypothyroidism).

    Testing for TBG, TRH, and reverse T3 is explicitly listed as not meeting coverage criteria.

    CC9 summarizes that thyroid markers already addressed within the policy are not allowed for indications already addressed and states testing for thyroid markers during a general exam without abnormal findings does not meet coverage criteria.

    CPT code 83520 and CPT code 84442 were added to the coding section.

    TBG added as not covered under any circumstances.

    Thyroid antibody testing limited to once every three years for individuals with hypo- or hyperthyroidism.

    CC1 expanded to add screening for individuals who experienced two or more pregnancy losses and added annual screening for individuals with primary mitochondrial disease.

    CC1 edited to add pediatric indication for failure-to-thrive.

    CPT 84442 was added (then later removed in coding enhancement).

    1 per 6 wksTSH frequency (when indicated)
    3-monthlyTSH frequency (IRT/meds)
    6 wksfT4 monitoring (dose changes)
    3-yearAntibody testing interval
    TBG/TRH/rT3Not covered tests
    ≈0.01TSH assay sensitivity

    Coverage Criteria Overview & Clinical Rules

    inv-01: Covered testing and monitoring

    Covered when the specified clinical indication and frequency criteria are met

    TSH initial/diagnostic coverage

    • Signs/symptoms: For individuals with signs and symptoms consistent with hypothyroidism or hyperthyroidism (see policy Notes)
    • Suspected secondary hypothyroidism: For individuals with suspected secondary (central) hypothyroidism
    • Recurrent pregnancy loss: For individuals capable of becoming pregnant who have experienced two or more pregnancy losses
    • Thyroid nodule: For individuals with a thyroid nodule
    • Pregnancy history: For pregnant individuals with a personal history of thyroid dysfunction
    • At-risk and special populations: For individuals with type 1 diabetes, chronic or acute urticaria, primary mitochondrial disease, pediatric short stature or failure-to-thrive, or disease/neoplasm of the thyroid or other endocrine glands
    Allowed TSH frequency: When covered as above, TSH may be measured no more than one test every six weeks for the listed indications; for individuals undergoing immune reconstitution therapy (including alemtuzumab), post-transplant (BMT/HSCT), on HAART, or taking medications known to cause thyrotoxicosis (e.g., amiodarone, interferon-α, interleukin-2, lithium, tyrosine kinase inhibitors), allowed frequency is once every three months.

    Reflex testing after abnormal TSH

    • fT4 reflex: Free T4 (fT4) as follow-up to abnormal TSH findings
    • T3 testing for low TSH: Total T3 (TT3) and free T3 (fT3) to confirm diagnosis of hyperthyroidism when TSH is below the normal range
    • fT4/fT3 for IRT: fT4 and fT3 for individuals undergoing immune reconstitution therapy
    Pregnancy/postpartum monitoring: Monitoring of TSH and/or fT4 meets coverage criteria once every four weeks for pregnant or postpartum individuals with symptoms of thyroid dysfunction; when treating hypothyroidism in pregnancy adjust levothyroxine with TSH monitoring every 4–6 weeks until mid-pregnancy.
    Monitoring primary hypothyroidism: For individuals treated for primary hypothyroidism: measure TSH every six weeks when dosages are actively changing; annually in stable individuals
    Monitoring primary hyperthyroidism: For individuals treated for primary hyperthyroidism: measure TSH and fT4 every eight weeks for the first year; annual monitoring thereafter
    Monitoring hypothalamic-pituitary disease: For individuals with hypothalamic-pituitary disease: biannually if <18 years of age and annually if ≥18 years
    Primary mitochondrial disease: Annual monitoring of TSH and fT4 for individuals diagnosed with primary mitochondrial disease
    Secondary hypothyroidism monitoring: For individuals being treated for secondary hypothyroidism, monitor fT4 every six weeks when dosages are actively changing and annually when stable
    Thyroid antibody testing interval: For individuals with hypothyroidism or hyperthyroidism (including those without diagnosed autoimmune thyroid disease), testing for thyroid antibodies (eg, Tg‑Ab, TPOAb, TRAb, TSI) meets coverage criteria once every three years
    Thyroid cancer surveillance: For individuals with differentiated thyroid carcinoma, measurement of serum thyroglobulin (Tg) and Tg‑Ab for detection of recurrence, post-surgical evaluation, surveillance, and maintenance meets coverage criteria per ATA recommendations (eg, Tg measured 6–12 weeks post‑op and with subsequent surveillance)

    inv-02: Covered when consistent with specialty guideline indications and monitoring

    Coverage aligns with guideline-recommended indications and monitoring:

    Pregnancy testing guidance: When testing is indicated in pregnancy, use TSH as first‑line screening; monitor TSH every 4–6 weeks while adjusting levothyroxine aiming for a TSH between the lower reference limit and ~2.5 mU/L; use fT4 or TT4 with pregnancy‑specific reference ranges as recommended for hyperthyroidism monitoring and consider total T3 when T3 thyrotoxicosis is present
    Indications for testing in pregnancy: Indicated testing in pregnancy includes personal or family history of thyroid disease, type 1 diabetes, clinical suspicion, significant goiter, or distinct thyroid nodules; routine TPO antibody testing in euthyroid women is not recommended
    Specialty indications: ATA/AACE recommend TSH testing for multiple clinical contexts (eg, type 1 diabetes, unexplained cardiac or metabolic findings) and prefer fT4 over total T4 for diagnosing hypothyroidism except in pregnancy where total T4 or assay‑specific fT4 methods may be required
    Avoid routine population screening:

    inv-03: Covered when clinically indicated per specialist society guidance

    Coverage-relevant clinical testing guidance reflected in society positions (used to inform medical necessity determinations):

    Initial evaluation of suspected thyroid dysfunction: Start with serum TSH; if TSH is abnormal or unreliable (eg, suspected pituitary disease, assay interference, or rapidly changing function), obtain fT4 and/or fT3 as appropriate; confirm diagnoses with fT4 testing as recommended
    Pregnancy-specific testing: Apply trimester‑specific TSH reference ranges; measure TSH early in pregnancy for at‑risk women and monitor every 4 weeks until mid‑pregnancy when managing hypothyroidism; use method‑specific fT4 or TT4 with pregnancy‑adjusted ranges if fT4 assay performance is limited
    Antibody testing guidance: Consider TPOAb in subclinical hypothyroidism and in recurrent miscarriage; measure TRAb in pregnant patients with prior Graves' disease or prior ablation at recommended gestational windows
    Avoid routine T3 testing: ATA/AACE recommend against routine serum T3 or fT3 testing for diagnosing hypothyroidism; reserve T3 testing for specific indications such as characterizing T3‑predominant thyrotoxicosis

    inv-04: Initial and cascading testing

    Covered testing approach when evaluating suspected thyroid dysfunction

    Initial evaluation: Begin with TSH measurement rather than ordering multiple tests simultaneously
    Cascading tests based on TSH: If TSH is above the reference range → measure free T4 in the same sample; if TSH is below the reference range → measure free T4 and free T3 in the same sample; consider measuring both TSH and fT4 when secondary thyroid dysfunction is suspected or for children/young people

    inv-05: IRT and alemtuzumab monitoring

    Monitoring around immune reconstitution therapy (IRT) and alemtuzumab

    Pre-IRT testing: Measure TSH in all subjects prior to immune reconstitution therapy; if abnormal, obtain fT4 and fT3
    Post-IRT and alemtuzumab monitoring: For alemtuzumab-treated individuals perform biochemical follow‑up with TSH every 3 months and continue routine three‑monthly thyroid function testing for 4 years after last treatment; post-IRT TSH should be repeated per ETA guidance with fT4 added when indicated

    inv-06: Central hypothyroidism evaluation

    Criteria for considering central hypothyroidism (CeH)

    Consider CeH when: Screening shows low fT4 with low or inappropriately normal TSH, or low fT4 with TSH levels that are not appropriate for the degree of hypothyroidism
    Confirm CeH: Confirm diagnosis by documenting low fT4 with inappropriately low/normal TSH on at least two separate determinations and by excluding other listed conditions per guideline
    Monitoring in hypothalamic‑pituitary disease: In patients under follow‑up for hypothalamic‑pituitary disease, monitor fT4 and TSH biannually in childhood and yearly in adulthood; consider CeH when fT4 falls into the lower quartile or drops >20% from prior values with low/normal TSH

    inv-07: Monitoring schedules

    Monitoring intervals for specific populations and therapies (NICE summary)

    Levothyroxine initiation in adults: Measure TSH every 3 months until stable (two similar measurements within reference range 3 months apart), then annually
    Children on levothyroxine: Children ≥2 years: measure fT4 and TSH every 6–12 weeks until TSH stabilizes, then every 4–6 months until after puberty, then yearly; children <2 years: measure fT4 and TSH every 4–8 weeks until stabilized, then as specified by age
    Antithyroid drug monitoring: For patients on antithyroid drugs measure TSH, fT4, and fT3 every 6 weeks until TSH normalizes, then TSH (with cascading) every 3 months while on therapy; after stopping, follow the specified post‑cessation monitoring intervals

    inv-08: Coverage criteria (overview)

    Coverage is structured into multiple Clinical Criteria (CC) groups addressing initial screening, follow-up after abnormal results, monitoring in special conditions, and exclusions.

    CC1 - Initial screening and monitoring: TSH is first‑line testing for most indications; includes subcriteria for diagnostic evaluation, at‑risk screening, pregnancy, pediatric indications, and monitoring intervals during treatment. Reflex to fT4/fT3 per abnormal TSH.
    CC2 - Follow-up testing for abnormal TSH: Follow‑up testing (eg, fT4, fT3, TT3) meets coverage when TSH is abnormal per clinical guidance.
    CC3 - Monitoring when fT4 initial monitoring allowed: Monitoring of TSH and fT4 when conditions allow initial monitoring with fT4 without requiring abnormal TSH (eg, certain secondary hypothyroidism scenarios) meets criteria.
    CC4 - Monitoring fT4 without additional TSH (secondary hypothyroidism): For secondary/central hypothyroidism, fT4 monitoring without TSH meets criteria with specified frequencies for dosage changes and stable patients.

    inv-09: Frequency limitation

    Summary of significant coverage criteria changes from revision history

    Antibody testing frequency change: Thyroid antibody testing for individuals with hypothyroidism or hyperthyroidism is limited to once every three years (documented as a revision).

    inv-10: Not covered tests

    Tests explicitly not meeting coverage criteria

    TRH or TBG and other excluded assays: Testing for thyrotropin‑releasing hormone (TRH), thyroxine‑binding globulin (TBG), reverse T3, or T3 uptake does NOT meet coverage criteria and is excluded under any circumstances.
    General non‑covered contexts: Testing for thyroid function markers during a general exam without abnormal findings or in situations not specifically listed in the coverage criteria does not meet coverage criteria and may be denied.

    inv-11: Added indications

    Expanded covered screening indications added

    Added pregnancy‑related indication: Added screening indication for individuals capable of becoming pregnant who have experienced two or more pregnancy losses
    Primary mitochondrial disease: Added annual TSH and fT4 screening for individuals diagnosed with primary mitochondrial disease
    Pediatric indication: Added pediatric screening indication for failure‑to‑thrive
    One‑time high‑risk TSH screening: Clarified allowance for one‑time TSH screening in selected asymptomatic high‑risk individuals (eg, family history, autoimmune disease, thyroid neoplasm, certain pediatric growth concerns)

    Testing for thyroxine-binding globulin (TBG), thyrotropin-releasing hormone (TRH), reverse T3, or T3 uptake does not meet coverage criteria and will be denied. These tests were explicitly listed in the policy revision history as exclusions and are operationally categorized as not covered under any circumstances. Providers should not submit requests for these assays when seeking medical necessity determinations for thyroid evaluation.

    Ordering any thyroid function markers (TSH, fT4, fT3, antibodies, etc.) during a routine general exam in an asymptomatic individual without abnormal findings does not meet coverage criteria and may be denied. The policy consolidates this as a general exclusion: testing during a general exam absent clinical signs or risk factors is not supported.

    The United States Preventive Services Task Force (USPSTF) finds current evidence insufficient to recommend screening for thyroid dysfunction in nonpregnant, asymptomatic adults; USPSTF also recommends against screening for thyroid cancer in asymptomatic adults. As a result, universal asymptomatic screening in this population is not supported by this policy.

    Universal population screening with TSH is not supported. Specialty guidance (e.g., ATA, ACOG, ASRM) recommends targeted testing in pregnancy and specific risk groups rather than universal prenatal or preconception TSH screening. For pregnant or at‑risk individuals follow pregnancy-specific recommendations (eg, start-of-pregnancy TSH measurement and repeat monitoring per trimester-specific guidance) rather than universal TSH screening.

    Routine TSH screening at well visits in asymptomatic adults is not recommended. The American Society for Clinical Pathology (ASCP) advises against TSH screening during routine annual well visits and recommends targeted testing for patients with risk factors or signs of thyroid dysfunction. Routine ordering of total or free T3 for screening or routine ultrasound without palpable abnormality is also discouraged.

    Per recent policy edits, tests including TBG, TRH, reverse T3, and T3 uptake are explicitly listed as not meeting coverage criteria. The revision history reclassifies these assays as denied/non-covered and highlights that they should not be ordered for evaluation of thyroid disease.

    Ordering thyroid markers as part of a general exam when there are no abnormal findings or risk factors is not covered and may be denied. The policy combines prior exclusions to make clear that non-targeted routine testing during general exams is not an acceptable indication for thyroid laboratory testing.

    TBG testing is excluded under any circumstances. The revision history explicitly adds TBG to the list of tests that do not meet coverage criteria and states it is not covered.

    Requests for testing not explicitly listed as meeting coverage criteria in this policy should be considered not medically necessary. The policy states that thyroid tests ordered for indications outside the specified coverage groups (including the tests explicitly excluded) do not meet criteria for coverage.

    Routine measurement of serum T3 or free T3 (fT3) is not useful for diagnosing hypothyroidism and is recommended against by ATA/AACE guidance; fT3/TT3 testing is generally reserved for specific situations (for example, confirmation of thyrotoxicosis when TSH is low), not routine hypothyroidism diagnosis.

    The policy discourages ordering multiple initial thyroid tests simultaneously. Consistent with ASCP and NICE recommendations, initial evaluation should begin with TSH and then cascade to fT4 (and fT3 if indicated) based on the TSH result rather than ordering broad panels upfront.

    ASCP guidance discourages multiple upfront tests for initial thyroid evaluation and supports a cascade approach: start with TSH, then measure fT4 if TSH is abnormal, and add fT3/TT3 when TSH is low and hyperthyroidism is suspected. This stepwise approach limits unnecessary testing and aligns with the policy's coverage logic.

    Ordering TBG, TRH, reverse T3, or T3 uptake for the evaluation of thyroid disease is considered not medically necessary and does not meet the policy's coverage criteria. These assays are specifically identified in the policy exclusions and revision history as non-covered tests.

    Testing with TRH does not meet coverage criteria for evaluating the cause of hyperthyroidism or hypothyroidism. The policy revision history reclassifies TRH testing as not meeting coverage criteria and subject to denial.

    Procedure and Billing Codes

    No explicit CPT/HCPCS/ICD codes in this document segmentmixed
    No codes listed
    Referenced procedure codesCPT
    80438Thyrotropin-releasing hormone (TRH) stimulation panel; 1 hour (must include TSH 84443 x 3)
    80439Thyrotropin-releasing hormone (TRH) stimulation panel; 2 hour (must include TSH 84443 x 4)
    83519Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
    83520Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
    84432Thyroglobulin
    84436Thyroxine; total
    84439Thyroxine; free
    84442Thyroxine-binding globulin (TBG)
    84443Thyroid stimulating hormone (TSH)
    84445Thyroid stimulating immune globulins (TSI)
    1–10 of 16
    1/2
    Referenced CPT/HCPCS and lab codesCPT
    80438Thyrotropin-releasing hormone (TRH) stimulation panel; 1 hour (panel must include TSH x3)
    80439Thyrotropin-releasing hormone (TRH) stimulation panel; 2 hour (panel must include TSH x4)
    83519Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
    83520Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
    84432Thyroglobulin
    84436Thyroxine; total
    84439Thyroxine; free
    84442Thyroxine-binding globulin (TBG)
    84443Thyroid stimulating hormone (TSH)
    84445Thyroid stimulating immune globulins (TSI)
    1–10 of 16
    1/2
    Coding changes / Removed or not coveredCPTNot Covered
    84437CPT code removed per coding enhancement
    84442CPT code added then removed per revision history
    S3620Removed from coverage
    80438No longer covered
    80439No longer covered
    inv-30: TSH assay detection limit — analytical sensitivity (~0.01 mU/L)
    Analytical sensitivityCurrent chemiluminometric TSH assays have detection limits around 0.01 mU/L.
    Clinical relevanceDetection limit permits discrimination between euthyroidism and hyperthyroidism and is superior to older assays (~0.1 mU/L).
    Assay typeMost current-generation assays are chemiluminometric (high-sensitivity).
    inv-31: Antibody testing frequency — Once every 3 years for individuals with hypo- or hyperthyroidism
    Allowed intervalThyroid antibody testing (eg, Tg‑Ab, TPOAb, TRAb, TSI) is limited to once every 3 years for individuals with hypothyroidism or hyperthyroidism.

    Provider Responsibilities, Documentation & Prior Auth

    Prior Authorization

    Prior authorization — routine thyroid tests covered when meeting criteria

    Most routine thyroid laboratory tests are covered when ordered for indications and frequencies specified in the policy; the document does not list additional, separate prior authorization CPT/HCPCS requirements in the cited sections. When requesting authorization, use the exact procedure codes listed in the policy's coding section.

    • TSH meets coverage criteria for specified indications with frequency limits (e.g., ≤1 test every 6 weeks for many indications; once every 3 months for IRT/ale mtuzumab and certain drugs).
    • No separate PA-triggering CPTs are named in the indicated excerpts — confirm coding/authorization requirements with current payer systems prior to submission.
    Note

    Testing requirements — start with TSH; use fT4 (or TT4 in pregnancy)

    When screening or evaluating thyroid function, start with serum TSH as the first-line test; follow abnormal TSH with free T4 (fT4). In pregnancy, if trimester-specific fT4 reference ranges are unavailable, use total T4 (TT4) with pregnancy‑adjusted ranges or a free thyroxine index per specialty guidance.

    Clinical Background & Rationale

    Thyroid hormones produced by the thyroid gland are essential regulators of growth, development, and metabolic homeostasis across the lifespan. Thyroid disease encompasses hypothyroidism, hyperthyroidism, goiter, thyroiditis (including subacute and postpartum forms), nodules, and differentiated thyroid cancers. Clinical evaluation typically begins with TSH measurement as the preferred initial test, with free T4 (fT4) and T3/fT3 used to further characterize abnormalities or when pituitary disease is suspected.

    Key Definitions and Test Descriptions

    inv-58: TSH definition and role — TSH described as initial test
    DefinitionTSH (thyroid stimulating hormone) is secreted by the anterior pituitary and regulates thyroid hormone production.
    Role in testingTSH is the preferred initial test for assessment of thyroid function in most clinical situations (assuming steady state and no pituitary/hypothalamic disease).
    Use in cascade testingAbnormal TSH typically reflexes to measurement of free T4 (and free/total T3 when TSH is low) to characterize hypo‑ versus hyperthyroidism.
    inv-59: fT4 — free thyroxine preferred; pregnancy note on trimester-specific ranges
    Preferred analyteFree thyroxine (fT4) is the preferred measure of available thyroid hormone.
    Pregnancy consideration

    Policy Revision History

    2026-09-15policy_revisionLatest

    Clinical Advisory Board review; CC1 was edited and subdivided into CC1–CC4 to create a cascade approach (TSH vs fT4/fT3/TT3) and CC8 revised to explicitly state TBG, TRH, reverse T3, and T3 uptake do not meet coverage criteria.

    2023-03-10policy_revision

    Background, guidelines, and evidence references updated; CC1 expanded to add screening for individuals with two or more pregnancy losses, annual screening for primary mitochondrial disease, and a pediatric failure-to-thrive indication; CPT 84442 was added then removed in a coding enhancement.

    2022-05-15
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyThyroid Disease Testing
    Policy CodePolicy AHS - G2045 - Thyroid Disease Testing
    Change TypeSubstantive revision with new CC groups and clarified exclusions
    Effective DateSep 15, 2026
    Last ReviewSep 1, 2023
    Next Review DateN/A
    Key ActionStart evaluation with TSH and cascade to fT4/fT3 only when indicated; document clinical indication and applicable monitoring frequency.
    SourceLink
    On This Page
    Coverage Criteria Overview & Clinical RulesProcedure and Billing CodesProvider Responsibilities, Documentation & Prior AuthClinical Background & RationaleKey Definitions and Test DescriptionsPolicy Revision History
    USPSTF states evidence is insufficient to recommend screening asymptomatic, nonpregnant adults for thyroid dysfunction and recommends against thyroid cancer screening in asymptomatic adults
    CC5–CC8 - Other specified monitoring and indications: Includes monitoring frequencies for hypothyroidism (eg, every 6 weeks on dose change), hyperthyroidism (eg, every 8 weeks during treatment), pregnancy‑related testing allowances, and antibody testing rules.
    CC9 - General exclusions: For all other situations not mentioned above, testing for any thyroid function markers discussed in this policy (eg, testing during a general exam without abnormal findings) DOES NOT MEET COVERAGE CRITERIA.
    Applicable populationsIndividuals with diagnosed hypothyroidism or hyperthyroidism (including those without known autoimmune disease).
    Policy originFrequency restriction documented in the policy revision history and coverage criteria edits.
    • First-line screening: TSH measurement.
    • Reflex/follow-up: fT4 after abnormal TSH; TT3/fT3 when TSH is low to confirm hyperthyroidism.
    • Pregnancy: prefer trimester-specific fT4; if unavailable, use TT4 with pregnancy‑adjusted reference ranges or FT4 index.
    Prior Authorization

    Prior authorization requirements — not specified in excerpts

    The provided excerpts do not specify additional prior authorization rules beyond the coverage criteria; they state most routine thyroid tests meet coverage when clinical indications and frequency criteria are satisfied.

    • Policy indicates coverage is based on clinical indications and allowed frequencies rather than listing PA-only CPTs in these sections.
    • Confirm any payer-specific PA processes or code-level requirements before submitting.
    Billing Rule

    Procedure codes — use exact CPT/HCPCS codes from policy

    When requesting authorizations or billing, include the exact CPT/HCPCS procedure codes listed in the policy's coding table. Use these codes to identify the specific assay or panel being ordered.

    • Examples of listed codes: 80438, 80439, 83519, 83520, 84432, 84436, 84439, 84442, 84443, 84445, 84479, 84480, 84481, 84482, 86376, 86800.
    • Include the appropriate code(s) on authorization requests to match the test(s) performed.
    Billing Rule

    Procedure/coding — use listed CPTs; some tests (TBG/TRH/reverse T3) are non-covered

    Order and code tests exactly as listed; several specific assays are identified as not meeting coverage criteria and will be denied if billed. Do not submit authorization requests for tests explicitly listed as non-covered.

    • Tests listed in coding (e.g., 84442 TBG; 84482 reverse T3) are included for reference; however, TBG, TRH and reverse T3 are identified elsewhere as not meeting coverage criteria.
    • Requests for non-covered tests should not be expected to meet medical necessity and may be denied.
    Billing Rule

    Coding changes may affect authorization — confirm current code coverage

    Coding changes and removals are documented in the revision history; providers should confirm current code coverage and payer acceptance before submitting authorization or billing to avoid denials related to obsolete codes.

    • Revision history documents addition and later removal of certain CPTs (e.g., 84442 added then removed; codes 80438 & 80439 later marked as no longer covered).
    • Verify the payer's active code list and prior authorization requirements at the time of service.
    Step Therapy

    Step therapy — none described

    No step therapy or medication-step requirements are described in the provided policy excerpts.

    • Policy does not impose step therapy for ordering thyroid laboratory tests.
    • Clinical evaluation should still follow guideline-based sequencing (TSH first, then reflex tests as indicated).
    Step Therapy

    Stepwise testing — TSH first, confirm with fT4 before broader testing

    Follow a stepwise testing approach: measure TSH first and confirm abnormal results with fT4 before ordering broader panels or imaging.

    • Start with TSH for initial evaluation; confirm diagnosis with free T4.
    • Reserve TT3/fT3 for low TSH to establish hyperthyroidism rather than ordering broad panels initially.
    Step Therapy

    Cascading initial testing — TSH then reflex to fT4/±fT3

    Use a cascading testing strategy: obtain TSH first and then reflex to fT4 (and fT3/TT3 if indicated) rather than ordering multiple thyroid assays up-front.

    • If TSH above reference range → measure fT4 in same sample.
    • If TSH below reference range → measure fT4 and fT3 (or TT3) in same sample.
    Step Therapy

    Cascade testing approach — TSH first-line with reflex fT4/fT3 per criteria

    The policy defines a cascade approach with TSH as first-line and reflex/follow-up fT4/fT3 testing per specified scenarios; order tests accordingly to align with coverage criteria.

    • CC1–CC4 reorganized to emphasize TSH first-line and conditional follow-up testing.
    • Reflex testing for IRT/ale mtuzumab and pregnancy-specific monitoring are described in criteria.
    Documentation Required

    Documentation — record clinical indication and risk factors to support testing

    Document the clinical indication and patient risk factors when ordering thyroid tests (e.g., signs/symptoms of hypo- or hyperthyroidism, pregnancy status, medication exposures, history of thyroid disease or nodules, IRT/HAART/BMT/HSCT, recurrent pregnancy loss) and include timing/frequency of prior tests to support medical necessity.

    • Include signs/symptoms or specific risk factors that match policy criteria.
    • When applicable, document prior test dates and the monitoring plan (e.g., dose changes and intended recheck interval).
    Documentation Required

    Pregnancy testing documentation — indicate reason, reference ranges, and monitoring plan

    When testing pregnant patients, document the indication (personal/family history of thyroid disease, type 1 diabetes, clinical suspicion, infertility, or recurrent pregnancy loss), use trimester‑specific reference ranges when available, and document the monitoring plan and TSH targets or dose adjustments for levothyroxine.

    • Document pregnancy status and the specific reason for testing (risk factor or symptoms).
    • Record trimester-specific reference ranges or the use of TT4/FT4 index if FT4 assay is unreliable in pregnancy; document planned monitoring intervals (e.g., every 4–6 weeks while adjusting therapy).
    Documentation Required

    Document clinical indication and monitoring plan — specify recheck intervals

    Document a monitoring plan when ordering tests for treatment monitoring (e.g., state that TSH will be rechecked every 6 weeks during dose changes for primary hypothyroidism or that fT4 will be rechecked every 6 weeks for secondary hypothyroidism while doses change).

    • For primary hypothyroidism: document intent to recheck TSH every 6 weeks during dose titration and annually once stable.
    • For secondary hypothyroidism: document plan to monitor fT4 every 6 weeks during dose changes and annually when stable.
    Documentation Required

    Clinical indication documentation — tie orders to policy criteria

    Document clinical indications consistent with the policy's clinical criteria when ordering tests (e.g., risk factors, symptoms, pregnancy status, monitoring after treatment) to support medical necessity.

    • Tie orders to policy-listed indications (e.g., thyroid nodule, two or more pregnancy losses, IRT exposure).
    • Include relevant clinical notes in the medical record or authorization request.
    Step Therapy

    Cascading testing approach — avoid simultaneous broad panels

    Begin with TSH for initial evaluation and cascade to fT4 (and fT3/TT3 if indicated) rather than ordering broad panels; this reduces risk of denials for non-guideline testing.

    • ASCP and NICE recommend starting with TSH and only ordering follow-up tests based on TSH result.
    • Avoid ordering multiple initial thyroid assays simultaneously without documented indication.
    Denial Risk

    Denial risk — excluded tests (TBG, TRH, reverse T3, T3 uptake) will be denied

    Do not order tests that the policy explicitly excludes. Testing for thyroxine‑binding globulin (TBG), thyrotropin‑releasing hormone (TRH), reverse T3, or T3 uptake DOES NOT MEET COVERAGE CRITERIA and requests will be denied.

    • TBG is listed as excluded under any circumstances.
    • Requests for TRH or TBG testing for evaluation of the cause of hypo- or hyperthyroidism will be denied.
    Denial Risk

    Denial risk — non‑targeted routine screening may be denied

    Ordering thyroid tests during a general exam or routine well visit without abnormal findings or targeted clinical indication is not covered and may be denied; routine TSH screening in asymptomatic adults is discouraged by guideline bodies.

    • Do not perform non‑targeted TSH screening on asymptomatic adults during annual exams without documented risk factors or symptoms.
    • Document specific clinical findings or risk that justify testing to avoid denial.
    Note

    Government policy precedence — follow LCD/NCD/Medicaid when conflicting

    If this policy conflicts with an applicable government policy (e.g., Medicare LCD/NCD or state Medicaid), the government policy takes precedence and will be used to determine coverage.

    • Check applicable LCDs/NCDs or state Medicaid rules for members covered by those programs prior to requesting authorization.
    • When in doubt, follow the government policy applicable to the member.
    Denial Risk

    Excluded tests — TBG/TRH/reverse T3 classified as never covered

    Requests for testing thyroxine‑binding globulin (TBG), thyrotropin‑releasing hormone (TRH), or reverse T3 will be denied; the revision history and exclusions explicitly state these tests DO NOT MEET COVERAGE CRITERIA.

    • Policy revision history explicitly moved TBG/TRH/reverse T3 into the never-covered category (CC8/CC9).
    • Do not submit authorization/billing requests for these assays expecting coverage.
    Denial Risk

    Denied tests — TRH/TBG for etiologic evaluation will be denied

    Testing for TRH or TBG to evaluate the cause of hyperthyroidism or hypothyroidism does not meet coverage criteria and may be denied if submitted for that purpose.

    • Revision history explicitly states TRH/TBG testing for evaluation of cause of thyroid disease does not meet coverage criteria.
    • Codes previously associated with TRH panels (80438, 80439) were removed from coverage per coding changes.
    Note
    Note
    Note
    In pregnancy, trimester-specific and assay‑specific reference ranges for fT4 are required; if unavailable or discordant, total T4 (TT4) may be used with pregnancy‑adjusted ranges.
    Assay method noteWhen fT4 assays are unreliable in pregnancy, measurement by LC/MS/MS (dialysate or ultrafiltrate) or using a FT4 index/TT4 with adjusted ranges is advised.
    inv-60: Thyroid antibodies — TPO, TgAb, TRAb descriptions and uses
    Major antibodiesCommon thyroid antibodies include thyroglobulin antibody (Tg‑Ab), thyroid peroxidase antibody (TPOAb), and thyrotropin receptor antibodies (TRAb)/thyroid‑stimulating immunoglobulins (TSI).
    Clinical usesAntibody testing is used to evaluate autoimmune thyroid disease (eg, Hashimoto's, Graves'), guide diagnosis, and inform pregnancy risk (eg, TRAb in prior Graves' disease).
    Guideline recommendationsATA/AACE recommend considering TPOAb in subclinical hypothyroidism and recurrent miscarriage and TRAb measurement in pregnant patients with prior Graves' disease or ablation.
    inv-61: Subacute thyroiditis clinical course — recovery within 12-18 months note
    Clinical courseSubacute thyroiditis often presents with thyroid pain during the thyrotoxic phase (1–3 months) and follows a course similar to painless and postpartum thyroiditis.
    Recovery timelineMost individuals recover within 12–18 months; recovery rate cited as approximately 95% in this context.
    Associated causesDrug‑induced and radiation thyroiditis can cause transient thyrotoxicosis or permanent hypothyroidism depending on cause; acute infectious thyroiditis resolves with treatment.
    inv-62: TSH assay sensitivity — current chemiluminometric detection limits ~0.01 mU/L
    Detection limitCurrent chemiluminometric TSH assays have detection limits around 0.01 mU/L.
    ComparisonThis sensitivity is superior to prior-generation assays with detection limits near 0.1 mU/L.
    ImplicationHigh analytical sensitivity improves ability to distinguish euthyroid from hyperthyroid states.
    inv-63: Trimester-specific TSH reference ranges — ATA pregnancy ranges
    ATA pregnancy rangesATA‑recommended trimester‑specific TSH reference ranges: first trimester 0.1–2.5 mIU/L; second trimester 0.2–3.0 mIU/L; third trimester 0.3–3.0 mIU/L.
    Assay requirementMethod‑specific and trimester‑specific reference ranges for serum fT4 are required when measuring fT4 in pregnancy; consider TT4 with pregnancy‑adjusted ranges if fT4 assay unreliable.
    Monitoring frequencyEuthyroid but antibody‑positive pregnant women should have serum TSH measured at the start of pregnancy and every 4 weeks through mid‑pregnancy.
    inv-64: TPOAb and TRAb testing indications — use in subclinical hypothyroidism and recurrent miscarriage
    TPOAb indicationConsider TPOAb measurement when evaluating subclinical hypothyroidism and in patients with recurrent miscarriage.
    TRAb indicationMeasure TRAb in pregnant patients with a history of Graves' disease or prior radioactive iodine/thyroidectomy to assess fetal risk; timing examples include 20–26 weeks gestation with repeat if elevated.
    Guideline sourceRecommendations referenced from ATA/AACE guidance on antibody testing.
    inv-65: CeH — central hypothyroidism diagnosis definition
    Diagnostic definitionCentral (secondary) hypothyroidism should be considered when FT4 is low with low or inappropriately normal TSH; diagnosis confirmed by low FT4 on at least two separate determinations with inappropriately low/normal TSH and exclusion of other causes.
    Monitoring strategyIn suspected or confirmed central hypothyroidism, assess FT4 (and TSH as appropriate) and monitor FT4 during follow‑up rather than relying on TSH alone.
    Clinical contextCentral hypothyroidism is related to hypothalamic‑pituitary disease and TSH may be unreliable as a sole marker.
    inv-66: One-time TSH screening — definition for high-risk asymptomatic individuals
    DefinitionOne‑time TSH screening refers to a single TSH test performed in asymptomatic individuals at high risk (eg, personal/family history of thyroid disease, autoimmune disease, thyroid neoplasm, chronic/acute urticaria, pediatric short stature or failure‑to‑thrive).
    Use caseApplied for targeted, high‑risk asymptomatic population rather than universal screening of asymptomatic adults.
    DocumentationProviders should document the high‑risk indication when ordering one‑time screening to support medical necessity per policy guidance.
    inv-67: Secondary (central) hypothyroidism monitoring — monitoring uses fT4 (with/without TSH)
    Monitoring analyteFor secondary (central) hypothyroidism, monitoring uses free T4 (fT4) with or without TSH; TSH alone is unreliable.
    Frequency during dose changesWhen dosages are changing, monitor fT4 every 6 weeks; once stable, monitor annually.
    Pediatric considerationIn patients with hypothalamic‑pituitary disease, monitor both TSH and fT4 biannually for individuals <18 years and annually for adults, per guideline recommendations for surveillance.
    inv-68: TSH / fT4 abbreviation standardization — clarifications on terminology
    TSH abbreviationTSH = thyroid stimulating hormone; defined as the preferred initial test for thyroid function in steady state.
    fT4 abbreviationfT4 = free thyroxine; preferred measure of circulating available hormone and used as follow‑up to abnormal TSH or for central hypothyroidism monitoring.
    Terminology clarificationPolicy clarifies use of TSH and fT4 terms and testing sequences (start with TSH, then cascade to fT4/fT3 as indicated).
    initial_implementation

    Initial policy implementation and addition of CPT/code housekeeping changes later documented in subsequent updates (coding removal of S3620 and removal of coverage for 80438 & 80439 noted in later history).